Floatz logo

ETOMIDATE

Pancreatitis

Cheju Halla General HospitalSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Pancreatitis cohort.

Asset / SponsorPhaseRating
Meperidine
Cheju Halla General Hospital
Phase 4BB
MIDAZOLAM
Cheju Halla General Hospital
Phase 4BB
Pentoxifylline
Mayo Clinic
Phase 3BB
MAGNESIUM METALLICUM
University Medicine Greifswald
Phase 3BB
Pancrelipase
Dartmouth-Hitchcock Medical Center
Phase 2B
PROPOFOL
Assiut University
Phase 2CCC
PANTOPRAZOLE
Washington University School of Medicine
Phase 2CCC
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Assiut University
Phase 2CCC

Same molecule, other indications

ETOMIDATE is also rated in:

choledocholithiasisDormant
BB
Indicative ·
69 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
69 / 100
View asset →
schizophreniaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →